MedPath
HSA Approval

APO-HYDRALAZINE TABLET 25 mg

SIN00210P

APO-HYDRALAZINE TABLET 25 mg

APO-HYDRALAZINE TABLET 25 mg

April 5, 1988

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

C02DB02

hydralazine

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

APOTEX INC

Active Ingredients

HYDRALAZINE HCl

25 mg

Hydralazine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-HYDRALAZINE TABLET 25 mg - HSA Approval | MedPath